The RAF–MEK–ERK mitogen-activated protein kinase (MAPK) cascade is aberrantly activated in a diverse set of human cancers and the RASopathy group of genetic developmental disorders. This protein kinase cascade is one of the most intensely studied cellular signaling networks and has been frequently targeted by the pharmaceutical industry, with more than 30 inhibitors either approved or under clinical evaluation. The ERK–MAPK cascade was originally depicted as a serial and linear, unidirectional pathway that relays extracellular signals, such as mitogenic stimuli, through the cytoplasm to the nucleus. However, we now appreciate that this three-tiered protein kinase cascade is a central core of a complex network with dynamic signaling inputs and outputs and autoregulatory loops. Despite our considerable advances in understanding the ERK–MAPK network, the ability of cancer cells to adapt to the inhibition of key nodes reveals a level of complexity that remains to be fully understood. In this review, we summarize important developments in our understanding of the ERK–MAPK network and identify unresolved issues for ongoing and future study.
-
Cover Image
Cover Image
On the implications of the copper co-factor in lytic polysaccharide monooxygenase. A brief overview of structure, oxygen activation and application as bioindustrial process tools for decomposition of lignocellulose. Further information can be found in the review by Ipsen and colleagues (pages 531–540). Image provided by Katja Johansen.
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction Available to Purchase
Jennifer E. Klomp, Jeff A. Klomp, Channing J. Der; The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochem Soc Trans 26 February 2021; 49 (1): 253–267. doi: https://doi.org/10.1042/BST20200507
Download citation file:
Sign in
Sign in to your personal account
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Get Email Alerts
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |